ACCURBRON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACCURBRON (ACCURBRON).
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing cAMP and causing bronchodilation.
| Metabolism | Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation. |
| Excretion | Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug. |
| Half-life | Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients. |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg (wide distribution into tissues, including lungs). |
| Bioavailability | Oral: 60-80% (first-pass metabolism reduces bioavailability). |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-15 minutes. |
| Duration of Action | Oral: 12 hours (clinical effect persists for dosing interval); intravenous: 6-8 hours (dose-dependent). |
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 mL of 20% solution or 6-10 mL of 10% solution nebulized three to four times daily.
| Dosage form | SYRUP |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure. |
| Pediatric use | Inhalation: Infants and children: 1-2 mL of 20% solution or 2-4 mL of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used. |
| Geriatric use | No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ACCURBRON (ACCURBRON).
| Breastfeeding | Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available. |
| Teratogenic Risk | No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester. |
| Fetal Monitoring | Monitor maternal pulmonary function, fetal heart rate and growth via ultrasound if used during pregnancy. |
■ FDA Black Box Warning
No FDA boxed warning exists for this combination product.
| Serious Effects |
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
| Precautions | Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions. |
| Food/Dietary | High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use. |
Loading safety data…
| Fertility Effects | No known effect on fertility based on animal studies; human data not available. |
| Clinical Pearls | Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/mL. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets. |
| Patient Advice | Take exactly as prescribed; do not change dose without doctor approval. · Do not crush or chew sustained-release tablets. · Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia. · Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures. · Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits. · Keep regular appointments for blood tests to monitor drug levels. · Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor. |